BAX Global to manage GE returns
In industry parlance, it is reverse logistics. What it means is managing the return of parts and equipment for repair or substitution. GE Medical Systems has recruited BAX Global to handle this dark side of sales. Under the contract, the supply-chain
In industry parlance, it is reverse logistics. What it means is managing the return of parts and equipment for repair or substitution. GE Medical Systems has recruited BAX Global to handle this dark side of sales. Under the contract, the supply-chain management company will usher equipment rejected by clinics and hospitals to GE’s regional repair centers. GE’s 2000 field engineers will now be calling on BAX to handle their parts or equipment pickups inside hospitals. BAX will then follow through with the shipment of items that need repair to regional locations throughout the country. The company won the contract by promising reduced transportation costs and improved cycle time. BAX has been targeting the technology, aerospace, and healthcare markets, as they fit within the company’s core logistics competencies and experience. These markets account for the largest share of the company’s growth on a global basis.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
